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IdentifyingthegeneticcisassociationsbetweenDNAvariants(single-nucleotidepolymorphisms(SNPs))andgeneexpressionin
brain tissue may be a promising approach to ﬁnd functionally relevant pathways that contribute to the etiology of psychiatric
disorders. In this study, we examined the association between genetic variations and gene expression in prefrontal cortex,
hippocampus, temporal cortex, thalamus and cerebellum in subjects with psychiatric disorders and in normal controls. We
identiﬁed cis associations between 648 transcripts and 6725 SNPs in the various brain regions. Several SNPs showed brain
regional-speciﬁc associations. The expression level of only one gene, PDE4DIP, was associated with a SNP, rs12124527, in all
the brain regions tested here. From our data, we generated a list of brain cis expression quantitative trait loci (eQTL) genes that
we compared with a list of schizophrenia candidate genes downloaded from the Schizophrenia Forum (SZgene) database (http://
www.szgene.org/). Of the SZgene candidate genes, wefound that the expression levels of four genes, HTR2A,PLXNA2,SRR and
TCF4, were signiﬁcantly associated with cis SNPs in at least one brain region tested. One gene, SRR, was also involved in a
coexpression module that we found to be associated with disease status. In addition, a substantial number of cis eQTL genes
were also involved in the module, suggesting eQTL analysis of brain tissue may identify more reliable susceptibility genes for
schizophrenia than case–control genetic association analyses. In an attempt to facilitate the identiﬁcation of genetic variations
that may underlie the etiology of major psychiatric disorders, we have integrated the brain eQTL results into a public and online
database, Stanley Neuropathology Consortium Integrative Database (SNCID; http://sncid.stanleyresearch.org).
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Introduction
Schizophrenia, bipolar disorder and severe depression are
common and highly disabling brain diseases caused by an
interaction of genetic and environmental factors.
1,2 How-
ever, despite enormous efforts, the genetic variations that
contribute to these diseases and their environmental risk
factors remain elusive. Genome-wide association studies
have frequently been employed to identify susceptibility
genes and single-nucleotide polymorphisms (SNPs) that
may be associated with these mental disorders.
3–5 A number
of candidate genes for the disorders have been reported. For
instance, a web resource for schizophrenia, the Schizo-
phrenia Forum (SZgene) database (http://www.szgene.org/),
includes results from 1727 genetic association studies and
reports1008 candidate genes and 8788 polymorphisms in the
update on 15 April 2011.
6 Despite the numerous candidate
genes reported for schizophrenia, the effect size of each
variant is small or moderate and most associated SNPs
have failed to be replicated. The need for independent
and systematic validation to prioritize further examination
of possible candidate genes for mental disease is widely
acknowledged.
Identiﬁcation of DNA sequence variants that regulate gene
expression levels in a relevant tissue is one of the most
promising approaches used to initially scan for candidate
genes as well as to prioritize previously identiﬁed candidate
genes that are associated with complex disease such as
psychiatric disorders.
7–9 The identiﬁcation of a cis association
of a SNP with gene expression levels has been previously
used to validate candidate genes for complex traits mapped
to the same chromosomal locations.
10 Our recent study using
an integrative approach that combined results from genome-
wide SNP scans for the cytoarchitectural traits and cis
expression quantitative trait loci (eQTL) analysis in the
brain tissue revealed two novel candidate genes associated
with cellular abnormalities in the prefrontal cortex of major
psychiatric disorders.
11 Limited availability of human post-
mortem brain tissues is a major obstacle to obtaining detailed
brain expression complex trait loci (eQTL) mapping. Utiliza-
tion of publicly available resources is an effective alternative
strategy that may overcome such limitation. The Stanley
Neuropathology Consortium Integrative Database (SNCID;
http://sncid.stanleyresearch.org) is a publicly available and
web-based tool that integrates expression microarray data
sets from ﬁve brain regions including frontal cortex, temporal
cortex, thalamus, cerebellum and hippocampus and genome-
wide SNP genotype data sets of subjects in the Stanley
Neuropathology Consortium (SNC) and the Array Collection
(AC).
12 A total of 1749 neuropathology data sets using the
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www.nature.com/tpSNC are integrated into the database, which thereby enables
one to further explore the correlations between gene expres-
sion levels and quantitative measures of neuropathological
markers in the various brain regions. The speciﬁc aims of this
study are twofold. First, we explore the candidate genes that
may be functionally relevant for major psychiatric disorders
by identifying cis associations between SNPs and gene
expression in various brain tissues. Second, we examine the
possible functional role of schizophrenia candidate genes that
were previously identiﬁed in genetic association studies.
Thus, we explored cis eQTLs in the four brain regions, frontal
cortex, temporal cortex, thalamus and cerebellum, of SNC
subjects and in hippocampus of AC subjects. We also
repeated the analysis in frontal cortex data from the AC as a
replication study to examine the overall consensus of cis
eQTLs between the two frontal data sets. We then examined
whether the expression levels of any candidate genes from
theSZgenedatabasemeta-analysis(http://www.szgene.org/)
were regulated by cis expressed SNPs (eSNPs) in brain
tissues, in order to determine if there were any functional
effects on gene expression of the previously identiﬁed
schizophrenia susceptibility genes. Finally, we performed a
coexpression network analysis between the genes in the
frontal cortex that were differentially expressed between
schizophrenia and normal controls and the cis eQTL genes
in an attempt to identify the potential role of these genes in
a disease-speciﬁc coexpression module.
Materials and methods
Data used in this study. Gene expression microarray data
from frontal cortex,
13 cerebellum, thalamus and temporal
cortex
14were generated by multiple independent groups
using samples from the SNC (N¼60), which contains 15
well-matched cases in each of four groups: schizophrenia,
bipolar disorder, major depression and unaffected controls.
15
Other sets of microarray data from frontal cortex
16,17and
hippocampus were generated using samples from the AC
(N¼105). The AC is an independent tissue collection
containing 35 cases in each of three groups: schizophrenia,
bipolar disorder and unaffected controls. The groups from
both tissue collections are matched for descriptive variables
such as age, gender, race, post-mortem interval, mRNA
quality, brain pH and hemisphere. Outlier chip data were
excluded in this analysis based on previous quality-control
analyses for chip-level parameters such as scaling factor,
gene call and average correlation.
18 Information for the
microarray studies such as tissue collection, brain region and
number of outlier chips is listed in the Supplementary Table
S1 online. The confounding effects on the Frozen Robust
Multiarray Analysis (fRMA)-normalized microarray gene
expression data were identiﬁed using Surrogate Variable
Analysis (SVA).
19 To adjust disease effect on the gene
expression data, we randomly assign 0 or 1 for the primary
variable in the SVA. All covariates from SVA were used in
the linear regression to adjust the confounding effects on the
gene expression data. The standardized residuals from the
linear regression were used to evaluate the effectiveness of
this method on removing confounding variables on two
microarray data sets from both the SNC and AC. Transcripts
correlated with potential confounding variables were iden-
tiﬁed using nonparametric analysis. The continuous variables
such as age, brain pH, post-mortem interval and lifetime
exposure to antipsychotics were examined by correlation
analysis using R (open source program from Comprehensive
R Archive Network (CRAN)). Two categorical variables such
as microarray batch and sex were tested using variance
analysis. Adjusted P-values, based on the Hochberg method
that were o0.05, were considered signiﬁcant. Although all
cases and controls were included in the analysis, only the
disorder cases were used for the correlation analysis for the
effect of lifetime exposure to antipsychotics. SNP genotyping
data using DNA samples from the SNC and the AC were
generated by Dr Chun-Yu Liu and colleagues (University
of Chicago, IL, USA) using the Human SNP Array 5.0 chips
(Affymetrix, Santa Clara, CA, USA).
20
eQTL analysis. Raw image ﬁles from SNP chips, quality-
control analysis and identiﬁcation of ethnic outliers were
performed as previously described.
11 Brieﬂy, genotypes
were called using the BRLMM algorithm (Affymetrix). SNPs
with a call rate of o90%, minor allele frequency o5% or
extreme deviation from Hardy–Weinberg equilibrium test
(Po0.05) were ﬁltered out for further eQTL analyses. A total
of 309531 SNPs passed this ﬁlter. For examination of
population stratiﬁcation, clustering was initially performed
using the pairwise identity-by-state (IBS) calculator in the
PLINK.
21 IBS pairwise distances were then plotted and
examined by multidimensional scaling analysis and Z
statistical analysis. Samples of 43 s.d. compared with the
group mean were considered outliers. Four ethnic outliers
from the SNC and three outliers from the AC were excluded
in the eQTL analysis. One additional sample from AC was
excluded because of a ﬁnal diagnosis of CADASIL (cerebral
autosomal dominant arteriopathy with subcortical infarcts
and leukoencephalopathy). We only used genotyped SNP
data from chips for our association analysis rather than
imputing genotypes because SNP imputation can often result
in errors in genotyping and cause false-positive asso-
ciations.
22 The standardized residuals from the linear
regression were used as traits in PLINK for eQTL analyses.
We deﬁned cis eSNPs as those that were localized within
1Mb of either the 50 or the 30 end of the gene. The trans
eSNPs were deﬁned as all SNPs that reached genome-wide
signiﬁcance level, except those in a cis position. We employed
a conservative Bonferroni method to correct multiple testing
for controlling false positives.
7 Adjusted P-values of o0.05
(unadjusted P-value; 1.6E 07 ¼0.05/309531) were con-
sidered genome-wide signiﬁcant for eQTL analyses.
Coexpression network analysis. Unsupervised and
supervised coexpression network analyses were performed
using the Weighted Correlation Network Analysis (WGCNA)
in R.
23 The coexpression network was generated using
expression values of all genes in the frontal cortex of schizo-
phrenia and normal controls from the AC (unsupervised
WGCNA). A second coexpression network was generated
using signiﬁcant cis eQTL genes and genes that were
differentially expressed in the frontal cortex between
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(supervised WGCNA).
24 A total of four microarray data sets
(at www.stanleygenomics.org; study no. 1, 3, 5 and 7) were
generated from prefrontal cortex. Three of these (study no. 1,
3 and 7)
16,17 were generated using the same platform,
Affymetrix 133a, and hence to avoid variations between
platforms we pooled the data from these three data sets. The
pooled data were then subjected to median normalization
with the biometric research branch (BRB)-array tools (http://
linus.nci.nih.gov/BRB-ArrayTools.html) to remove systematic
variations. After median normalization, confounding effects
were adjusted using SVA and a linear regression method
as described in the previous section. However, disease
effect was not removed. Standardized residuals that were
signiﬁcantly associated with disease (nominal P-value
o0.05) and standardized residuals of cis eQTL genes were
then used as input for the WGCNA.
23 The minimum module
size and the minimum height for merging modules were set
at 30 and 0.25, respectively. The coexpression module was
visualized using VisANT.
25
Functional annotation. The cis eQTL genes and genes
that were involved in the coexpression module were functio-
nally annotated using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) database
(http://david.abcc.ncifcrf.gov/home.jsp) and by the over-
representational analysis method.
26 The biological processes
of Gene Ontology Consortium (http://www.geneontology.org)
were used for functional annotations. The P-values of o0.05
were considered signiﬁcant.
Results
eQTL analysis in various human post-mortem brain
tissues. Gene expression microarray data derived from
post-mortem brain tissue are often confounded by
uncontrolled biological, clinical and technical variables.
27
Batch effect is particularly problematic and has been shown
to signiﬁcantly affect gene expression levels in microarray
data.
28,29 To remove the effect of batch and other con-
founding variables in our gene expression microarray data,
we normalized the data using the newly developed method,
fRMA, followed by the SVA.
19,30 We evaluated how effective
this method was at removing confounding variables using
two microarray data sets from both the SNC and AC
(Supplementary Table S1 online). Using the data set from
SNC temporal cortex (study 18) we found that microarray
batch was the most signiﬁcant confounding variable in both
the RMA and fRMA-normalized data sets, with 947 and 1031
transcripts signiﬁcantly correlated with batch, respectively
(Supplementary Table S2 online). Using the data set from AC
frontal cortex (study 1) we found that microarray batch and
brain pH were both major confounding variables (Supple-
mentary Table S3 online). The SVA successfully adjusted the
effects of the confounding variables on both microarray data
sets (Supplementary Table S2 and S3 online).
Using the SVA weobtained thestandardized residuals from
the linear regression with covariates and conducted a
genome-wide eQTL analysis of various brain tissues. We
usedthestandardizedresidualsastraits.Weinitiallyanalyzed
geneexpressionmicroarraydatafromfrontalcortex,temporal
cortex, thalamus and cerebellum from the SNC (Supplemen-
tary Table S1 online). Expression levels of a total of 53, 11, 84
and 27 genes were correlated with cis SNPs in the frontal
cortex, temporal cortex, thalamus and cerebellum at genome-
wide signiﬁcance level, respectively (nominal Po1.6E 07;
Figure1aandSupplementaryTableS4online).Amongthecis
eQTL genes, expression levels of 16, 0, 20 and 5 genes were
also signiﬁcantly associated with trans SNPs in the frontal
cortex, temporal cortex, thalamus and cerebellum, respec-
tively (Supplementary Table S5 online). In addition, correla-
tions between the expression levels of 31, 1, 69 and 15 genes
and cis SNPs were unique in the frontal cortex, temporal
cortex, thalamus and cerebellum, respectively (Figure 1a).
The expression level of only one gene, phosphodiesterase 4D
interacting protein (PDE4DIP), was associated with a SNP,
rs12124527, in all the brain regions tested here. We then
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Figure 1 Numberofcisexpressionquantitativetraitloci(eQTL)genesinvariousbrainregions.VenndiagramshowscommonanduniqueciseQTLgenesacrossmultiple
brain regions of the Stanley Neuropathology Consortium (SNC) samples (a) and of the Array Collection (AC) samples (c). Overlapped cis eQTL genes in the frontal cortex
between the SNC samples and the AC samples are shown (b).
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AC collection. The replication study revealed associations
between cis SNPs and expression levels of 460 genes and
replicated 34 cis eQTL genes out of 53 (64%) that were
identiﬁed in the SNC study (Figure 1b and Supplementary
Table S6 online). Moreover, 281 cis eQTL genes were
identiﬁed in the AC hippocampus data and 147 cis eQTLs
were common to both the frontal cortex and hippocampus
(Figure 1c and Supplementary Table S7 online). Among the
cis eQTL genes, expression levels of 43 and 46 genes
were also signiﬁcantly associated with trans SNPs in the
frontal cortex and hippocampus, respectively (Supplementary
Table S5 online). The association between PDE4DIP
expression and the rs12124527 SNP was replicated in the
AC frontal cortex and hippocampal data.
Next, we performed a functional annotation analysis to
identify biological processes that were overrepresented in the
brain cis eQTL genes. Whereas several processes such as
cell adhesion, visual perception and glutamatergic transmis-
sion were overrepresented in the genes with cis eSNPs in
the SNC frontal cortex (Table 1), metabolic processes such
as glutamine metabolic process and protein transport and
targeting and antigen processing were overrepresented in the
AC frontal cortex (Table 2). Amino acid metabolic process,
nucleotide biosynthesis and enzyme-linked receptor protein
signaling pathways were signiﬁcantly overrepresented in cis eQTL
genesintheAChippocampus(SupplementaryTableS8online).
Comparison between schizophrenia susceptibility
candidate genes and brain cis eQTL genes. Genetic
association studies have yielded numerous candidate genes
that may increase the risk for schizophrenia. However, most
candidate genes have not been replicated nor functionally
validated. To examine the possible functional role of
schizophrenia candidate genes, we compared the list of the
candidate genes in the SZgene database meta-analysis
(updated 12/1/2010) to our list of cis eQTL genes. The
SZgene meta-analysis identiﬁed 45 genetic variants and 42
linked genes. After excluding the non-SNP variants from their
data set, we were left with 39 SNPs and 39 linked candidate
genes. Because only 6 SNP markers out of the 39 SNPs
were included in our Affymetrix SNP 5.0 data set, we
conducted a gene-level comparison instead of SNP-level
comparison. We determined whether there were cis asso-
ciations between the expression levels of the 39 candidate
genes and SNPs within 1Mb of the genes. Among the 39
candidate genes, we found that the expression levels of four
genes, HTR2A, PLXNA2, SRR and TCF4, were signiﬁcantly
associated with cis SNPs in at least one brain region tested
(Table 3). The expression levels of HR2A and PLXNA2 were
associated with cis SNPs in the frontal cortex, whereas the
expression levels of SRR (serine racemase) and TCF4 were
associated with cis SNPs in two brain regions. The cis
eSNPs of these genes are located at least 25kb from the
SNPs that were signiﬁcantly associated with schizophrenia in
the SZgene meta-analysis. Thus the SZgene case–control
genetic association analyses for schizophrenia may not have
identiﬁed the most functionally relevant genetic variations
that contribute to the etiology of psychiatric disorders.
Coexpression network analysis in the frontal cortex. To
further examine whether or not the four schizophrenia candi-
date genes (HTR2A, PLXNA2, SRR and TCF4) and genes of
which expression levels were regulated by cis SNPs may be
involved in the etiology of schizophrenia, we performed both
unsupervised and supervised gene coexpression network
analyses using the AC frontal cortex data. We were unable
to construct a coexpression module that was signiﬁcantly
associated with schizophrenia disease status using the
unsupervised analysis. One module was associated with
disease (P¼0.05); however, it was also associated with
post-mortem interval (P¼0.01). We then constructed a
supervised coexpression network using genes differentially
expressed between schizophrenia and normal controls
(Supplementary Table S9 online) and the cis eQTL genes
obtained from the pooled data of three Affymetrix 133a
microarray data sets that measured gene expression in the
frontal cortex. We constructed one coexpression module that
was signiﬁcantly associated with schizophrenia disease
status (P¼2E 08; Figure 2a). Age, sex, post-mortem
interval, brain pH and lifetime antipsychotic treatment were
not signiﬁcantly associated with this module (all P40.05).
Genes associated with apoptosis, chromatin organization,
RNA splicing, cell cycle, regulation of nucleic acid metabo-
lism and endocytosis were overrepresented in this module
(Figure 2b and Supplementary Table 10 online). A previous
coexpression network analysis that used gene expression
microarray data from prefrontal cortex from schizophrenia
subjects and controls
31 also identiﬁed a module (module 16)
with similar overrepresentation of biological processes such
as chromatin organization, cell cycle, endocytosis and regu-
lation of nucleic acid metabolism. Apoptosis and endocytosis
have previously been associated with the pathophysiology
of the frontal cortex in schizophrenia,
32–44 and recent studies
have also indicated that aberrant RNA splicing and epi-
genetic alterations may be involved in the pathophysiology
Table 1 Biological processes (Gene ontology) signiﬁcantly associated with cis eQTL genes in the frontal cortex of the Stanley Neuropathology Consortium samples
Biological process categories Count Fraction (%) P-value
GO:0007155–cell adhesion 7 1.361868 0.013
GO:0022610–biological adhesion 7 1.361868 0.013
GO:0007601–visual perception 4 0.77821 0.022
GO:0050953–sensory perception of light stimulus 4 0.77821 0.022
GO:0046907–intracellular transport 6 1.167315 0.036
GO:0035249–synaptic transmission, glutamatergic 2 0.389105 0.039
Abbreviations: eQTL, expression quantitative trait loci; GO, Gene Ontology.
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35,36 Several genes associated with
GABAergic neurons, including g-aminobutyric acid (GABA)
A receptor, d (GABRD) and parvalbumin (PVALB), were
found in the coexpression module. However, out of the four
schizophrenia candidate genes common to both the SZgene
meta-analysis and our cis eQTL gene list, only one, SRR,
was found in the module. The biological process, response to
drug, was overrepresented in the module and was enriched
with 11 genes including SRR. A substantial number of cis
eQTL genes were involved in the coexpression module
Table 3 Schizophrenia candidate genes (from the SZgene database) with expression levels signiﬁcantly associated with cis eSNPs in brain tissue
Symbol Chr. Position
a Study_ID Brain_Region SNP S_Position P-value
b Adjusted P-value
HTR2A 13 (R): 47407513-47470175 Study01 Frontal cortex rs1923882 47411661 3.08E 10 9.45E 05
HTR2A 13 (R): 47407513-47470175 Study07 Frontal cortex rs1923882 47411661 2.54E 08 7.80E 03
PLXNA2 1 (R): 208195587-208417665 Study01 Frontal cortex rs6659522 208199100 3.26E 10 1.00E 04
PLXNA2 1 (R): 208195587-208417665 Study03 Frontal cortex rs6659522 208199100 1.03E 09 3.15E 04
PLXNA2 1 (R): 208195587-208417665 Study07 Frontal cortex rs6702082 208206946 4.04E 08 1.24E 02
SRR 17 (F): 2207248-2228553 Study01 Frontal cortex rs16952025 2116798 3.24E 08 9.94E 03
SRR 17 (F): 2207248-2228553 Study03 Frontal cortex rs16952025 2116798 8.86E 08 2.72E 02
SRR 17 (F): 2207248-2228553 Study07 Frontal cortex rs16952025 2116798 1.65E 13 5.06E 08
SRR 17 (F): 2207248-2228553 Study17 Hippocampus rs16952025 2116798 9.60E 11 2.95E 05
TCF4 18 (R): 52889562-53255860 Study01 Frontal cortex rs1261085 52889967 1.08E 08 3.33E 03
TCF4 18 (R): 52889562-53255860 Study03 Frontal cortex rs1261134 52931763 1.98E 15 6.09E 10
TCF4 18 (R): 52889562-53255860 Study05 Frontal cortex rs1261073 52907820 2.18E 12 6.68E 07
TCF4 18 (R): 52889562-53255860 Study07 Frontal cortex rs1261073 52907820 1.57E 15 4.82E 10
TCF4 18 (R): 52889562-53255860 Study16 Thalamus rs1261134 52931763 3.86E 08 1.18E 02
Abbreviation: eSNP, expressed single-nucleotide polymorphism.
Genome build;hg19.
aF and R represent the forward orientation or reverse orientation on a chromosome.
bAdjusted P-value using Bonferroni method.
Table 2 Biological processes (Gene ontology) signiﬁcantly associated with cis eQTL genes in the frontal cortex of the Array Collection samples
Biological process categories Count Fraction (%) P-value
GO:0006541–glutamine metabolic process 6 0.13 5.00E 05
GO:0009064–glutamine family amino acid metabolic process 8 0.17 1.50E 04
GO:0006412–translation 19 0.41 5.10E 04
GO:0046907–intracellular transport 28 0.60 1.80E 03
GO:0006414–translational elongation 9 0.19 2.00E 03
GO:0009069–serine family amino acid metabolic process 5 0.11 2.50E 03
GO:0034613–cellular protein localization 19 0.41 5.50E 03
GO:0070727–cellular macromolecule localization 19 0.41 5.80E 03
GO:0002474–antigen processing and presentation of peptide antigen via MHC class I 4 0.09 6.00E 03
GO:0002483–antigen processing and presentation of endogenous peptide antigen 3 0.06 7.10E 03
GO:0019885–antigen processing and presentation of endogenous peptide antigen via MHC class I 3 0.06 7.10E 03
GO:0006508–proteolysis 37 0.79 7.60E 03
GO:0006605–protein targeting 12 0.26 9.50E 03
GO:0006886–intracellular protein transport 17 0.36 1.10E 02
GO:0019882–antigen processing and presentation 7 0.15 1.10E 02
GO:0046777–protein amino acid autophosphorylation 7 0.15 1.20E 02
GO:0015031–protein transport 28 0.60 1.30E 02
GO:0019883–antigen processing and presentation of endogenous antigen 3 0.06 1.30E 02
GO:0045184–establishment of protein localization 28 0.60 1.40E 02
GO:0051603–proteolysis involved in cellular protein catabolic process 23 0.49 1.70E 02
GO:0044257–cellular protein catabolic process 23 0.49 1.70E 02
GO:0043632–modiﬁcation-dependent macromolecule catabolic process 22 0.47 2.00E 02
GO:0019941–modiﬁcation-dependent protein catabolic process 22 0.47 2.00E 02
GO:0001510–RNA methylation 3 0.06 2.00E 02
GO:0044265–cellular macromolecule catabolic process 26 0.56 2.30E 02
GO:0030163–protein catabolic process 23 0.49 2.40E 02
GO:0009070–serine family amino acid biosynthetic process 3 0.06 2.40E 02
GO:0048002–antigen processing and presentation of peptide antigen 4 0.09 2.40E 02
GO:0008104–protein localization 30 0.64 2.50E 02
GO:0007143–female meiosis 3 0.06 2.90E 02
GO:0044271–nitrogen compound biosynthetic process 14 0.30 3.20E 02
GO:0006607–NLS-bearing substrate import into nucleus 3 0.06 3.30E 02
GO:0034660–ncRNA metabolic process 11 0.24 3.50E 02
GO:0006625–protein targeting to peroxisome 3 0.06 3.80E 02
GO:0043574–peroxisomal transport 3 0.06 4.40E 02
GO:0009057–macromolecule catabolic process 26 0.56 4.70E 02
GO:0006399–tRNA metabolic process 7 0.15 5.00E 02
Abbreviations: eQTL, expression quantitative trait loci; GO, Gene Ontology; MHC, major histocompatibility complex; NLS, nuclear localization signal; tRNA, transfer
RNA.
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status and were also associated with the biological
processes. This result indicates that cis eQTL analysis in
brain tissue may more reliably identify susceptibility genes for
schizophrenia as compared with the current case–control
genetic association studies.
Discussion
Identifying genetic variations that affect gene expression in
the brain may be a promising approach for ﬁnding molecular
pathways that are functionally relevant to the etiology and/or
treatment of mental disease. In this study, we conducted an
eQTL analysis of 315440 transcripts in 5 different brain
regions from two different tissue collections and identiﬁed
cis associations between 648 transcripts and 6725 SNPs.
The expression of one gene, PDE4DIP, was associated with
one SNP, rs12124527, in all brain regions examined. This
association was also previously described in the frontal
cortex.
20 The protein encoded by PDE4DIP serves to anchor
phosphodiesterase 4D to the Golgi/centrosome region of the
cell. A number of abnormalities in the phosphodiesterase
signaling system have been described in the brains of
subjects with schizophrenia, bipolar disorder and depres-
sion,
37–42 indicating that molecules within this system could
be potential targets for therapeutic intervention.
38,43
Approximately 14% of cis eQTL genes were also correlated
with trans SNPs in various brain regions, suggesting that the
expression levels of a subset of cis eQTL genes may be
regulated by multiple variants. However, when we examined
whether or not the expression levels of candidate genes from
the SZgene database meta-analysis were signiﬁcantly asso-
ciated with cis SNPs, we found only 4 genes that over-
lappedbetweentheSZgenedatabaseandoureQTLgenelist.
Furthermore, only one candidate gene, SRR, was involved in
a coexpression module that was associated with schizo-
phrenia. SRR maps to chromosome 17p13 and encodes
an enzyme that synthesizes D-serine from L-serine.
44 The
D-serine is an endogenous co-agonist of the N-methyl-D-
aspartate (NMDA) receptor.
45 Hypofunction of the NMDA
receptor is potentially a major underlying pathophysiology of
schizophrenia.
46,47 Our results support this hypothesis and
suggest that abnormal NMDA receptor-mediated signaling
may be inﬂuenced by genetic variations. A SNP, rs16952025,
localized in an intron of the neighboring gene, SMG6, was
signiﬁcantly associated with the expression level of SRR.
However, there was no signiﬁcant association between this
SNP and the expression level of SMG6. Several post-mortem
studies have examined levels of SRR mRNA and serine
racemase protein in schizophrenia
48 and found abnormalities
in schizophrenia, although the results have been inconsistent.
Although SRR mRNA levels appear to be unchanged in
frontal cortex of schizophrenia,
41 the protein levels have
been reported to be either decreased,
49 increased
50 or
unchanged.
51 The inconsistent results are most likely
because of different methodologies, different cohorts (often
with small numbers) and the different brain areas used.
Consequently further study will be required in the future when
larger cohorts become available to conﬁrm changes in SRR
levels in the brain of subjects with mental illness.
Our comprehensive brain eQTL analysis functionally
validated only 4 genes out of 39 candidate genes positively
identiﬁed in the SZgene meta-analysis. We were unable to
identify any signiﬁcant associations between the expression
levels of the remaining genes and cis SNPs in any of the brain
regions we tested. In fact, the 39 candidate genes were
derived from 1008 candidate genes that were obtained
from 1727 original genetic association studies. Such a low
functional validation rate raises the possibility that the current
case–control genetic association studies may not effectively
Chromatin organization
RNA splicing
Response to drug
Endocytosis
No. of genes
0 51 0 1 5 2 0 2 5 30
Apoptosis
Cytoskeleton organization
Figure 2 Coexpression network analysis in the frontal cortex. The coexpression module that is signiﬁcantly associated with schizophrenia in frontal cortex of the Array
Collection (AC) (a) and biological processes (Gene ontology) overrepresented in the genes in the coexpression module (b). Network connections with topological overlap
above the threshold of 0.02 were visualized using VisANT.
25 The cis expression quantitative trait loci (eQTL) genes are pink. The candidate gene, SRR (serine racemase),
derived from the meta-analyses of genetic studies in the SZgene database (http://www.szgene.org/) is in blue.
Cis eQTLs in various brain regions
S Kim et al
6
Translational Psychiatryidentify genetic variations that underlie the etiology of
schizophrenia. However, there are other reasons that may
contribute to a low functional validation rate. For example, the
probes on the microarray platforms used to analyze gene
expression in this study mainly bind to sequences in the
30-untranslated regions and do not distinguish between
various alternative splicing isoforms. Indeed, tissue-speciﬁc
alternative RNA-splicing is very predominant in the brain.
52
Furthermore,intronicSNPscanbeassociatedwiththealtered
expression of speciﬁc alternative splicing isoforms of certain
schizophrenia candidate genes, for example, ErbB4 and
GRM3.
53,54 Therefore, comprehensive expression proﬁling
that includes various alternative splicing isoforms using deep
mRNA-sequencing technology may aid in the identiﬁcation of
novel cis eQTL genes in human post-mortem brain tissues in
the future.
The frontal cortex is one of the most thoroughly examined
brain regions in post-mortem studies and many neuropatho-
logy abnormalities have been identiﬁed in this region in
schizophrenia.
55,56 Previous gene expression microarray
studies in the frontal cortex identiﬁed several biological
processes that were overrepresented in the genes differen-
tially expressed between schizophrenia and normal controls;
for example, decreased presynaptic function, abnormal
mitochondrial function and altered expression of apoptosis-
related genes are all major ﬁndings from microarray studies of
frontal cortex in schizophrenia.
33,34,57 However, glutamater-
gic transmission, amino acid metabolism, proteolysis and
protein targeting were all overrepresented in the eQTL
genes in the frontal cortex in our current study. Thus, the
abnormalities described in the biological pathways from the
eQTL study may be more directly related to genetic variation,
whereas the pathways identiﬁed by gene expression studies
are likely to be inﬂuenced by factors in addition to genetic
variation, including epigenetics and environmental factors.
Although our study reveals a number of associations
between cis SNPs and gene expression in multiple brain
regions, the results should be interpreted with caution. First,
the SNC, which we used for the initial eQTL analyses,
contains a relatively small sample size (N¼56).Small sample
sizeisknowntogeneratehigherfalse-positiveassociationsas
well as to be a cause of low detection power in genome-wide
association analysis. Thus, the cis eQTL results from frontal
cortex, cerebellum, thalamus, and temporal cortex using SNC
samples should be viewed as exploratory. However, we
subsequently performed a second analysis using an inde-
pendent collection (AC) with a larger sample size (N¼101).
Our previous power analysis using AC as well as a previous
eSNP association study indicated that a relatively small
sample size (N¼100) has 480% power to detect an
association of gene expression traits with moderate effect
size (R
2¼0.35).
11,58 We therefore attempted to replicate the
results of cis eQTLs in frontal cortex from SNC using the AC
data. A total of 34 (64%) of the cis eQTL genes identiﬁed in
the SNC frontal cortex data were also found in the AC
frontal data. However, we identiﬁed 450 additional cis eQTL
genes in the AC frontal cortex samples, which were not
identiﬁed in the SNC frontal samples, suggesting that some
signiﬁcant cis eQTL genes may have been missed in the SNC
analysis.
Second, using whole tissues for gene expression traits may
dilute the effect of some genetic variants that may only act on
cell type-speciﬁc gene expression. Although this phenomena
has not been explored in the brain, there are numerous cell
type-speciﬁc abnormalities in the brain of subjects with
psychiatric disorders.
32,59–61 Thus, the use of cell type-
speciﬁc expression traits in future studies may increase the
power to identify cis eQTLs in the brain.
In this study, we investigated the associations between
SNPs and gene expression in various human brain regions.
Although previous brain eQTL studies focused on cortex,
8,62
we have extended the analysis to include the hippocampus,
thalamus and cerebellum. These data can be used to identify
genetic variations associated with psychiatric disorder and can
be used to identify genetic variations that affect neuropatho-
logical abnormalities and gene expression changes. As we
show in this study, the data can be used to functionally validate
candidate genes to determine if they are affecting changes in
geneexpressionin subjects with neuropsychiatric disorders. In
order to facilitate further studies, we have integrated the
genome-wide eQTL results from this study into the SNCID,
which is a web-based database that also includes 1747
neuropathological markers measured in the same SNC
samples. The update will allow users to investigate associa-
tions between SNPs and genes of interests in various brain
regions and to further explore associations between SNPs and
neuropathological markers and gene expression traits that are
correlated with neuropathological markers in the various brain
regions of subject with major psychiatric disorders.
Conﬂict of interest
The authors declare no conﬂict of interest.
Acknowledgements. We thank all the investigators who generated the
original data in the SNCID, and their many collaborators, who made this database
possible. We also thank all the technicians in the SMRI brain laboratory who
prepared the brain tissues and extracted the RNA and DNA from the tissues. We
specially thank the Keymind Company for their technical assistance with the
database, in particular Marvin Suo. We thank Dr Horvath for helpful comments on
networkanalysisusingtheWGCNA.HCandDLweresupportedbytheWorldClass
University program (R32-2008-000-10218-0) of the Ministry of Education, Science
and Technology through the National Research Foundation of Korea.
1. Mueser KT, McGurk SR. Schizophrenia. Lancet 2004; 363: 2063–2072.
2. SullivanPF,NealeMC,KendlerKS.Geneticepidemiologyofmajordepression:reviewand
meta-analysis. Am J Psychiatry 2000; 157: 1552–1562.
3. Purcell SM, Wray NR, Stone JL, Visscher PM, O’Donovan MC, Sullivan PF et al. Common
polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009;
460: 748–752.
4. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D et al.
Common variants conferring risk of schizophrenia. Nature 2009; 460: 744–747.
5. Sklar P, Smoller JW, Fan J, Ferreira MA, Perlis RH, Chambert K et al. Whole-genome
association study of bipolar disorder. Mol Psychiatry 2008; 13: 558–569.
6. Allen NC, Bagade S, McQueen MB, Ioannidis JP, Kavvoura FK, Khoury MJ et al.
Systematic meta-analyses and ﬁeld synopsis of genetic association studies in
schizophrenia: the SzGene database. Nat Genet 2008; 40: 827–834.
7. Dixon AL, Liang L, Moffatt MF, Chen W, Heath S, Wong KC et al. A genome-wide
association study of global gene expression. Nat Genet 2007; 39: 1202–1207.
8. Myers AJ, Gibbs JR, Webster JA, Rohrer K, Zhao A, Marlowe L et al. A survey of genetic
human cortical gene expression. Nat Genet 2007; 39: 1494–1499.
9. Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, Beazley C et al. Population
genomics of human gene expression. Nat Genet 2007; 39: 1217–1224.
10. EmilssonV,ThorleifssonG,ZhangB,LeonardsonAS,ZinkF,ZhuJetal.Geneticsofgene
expression and its effect on disease. Nature 2008; 452: 423–428.
Cis eQTLs in various brain regions
SK i met al
7
Translational Psychiatry11. Kim S, Webster MJ. Integrative genome-wide association analysis of cytoarchitectural
abnormalities in the prefrontal cortex of psychiatric disorders. Mol Psychiatry 2010; 16:
452–461.
12. Kim S, Webster MJ. The stanley neuropathology consortium integrative database: a novel,
web-based tool for exploring neuropathological markers in psychiatric disorders and the
biological processes associated with abnormalities of those markers. Neuropsycho-
pharmacology 2010; 35: 473–482.
13. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB et al.
Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 2003; 362:
798–805.
14. Aston C, Jiang L, Sokolov BP. Microarray analysis of postmortem temporal cortex from
patients with schizophrenia. J Neurosci Res 2004; 77: 858–866.
15. Torrey EF, Webster M, Knable M, Johnston N, Yolken RH. The stanley foundation brain
collection and neuropathology consortium. Schizophr Res 2000; 44: 151–155.
16. Iwamoto K, Bundo M, Kato T. Altered expression of mitochondria-related genes in
postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-
scale DNA microarray analysis. Hum Mol Genet 2005; 14: 241–253.
17. Ryan MM, Lockstone HE, Huffaker SJ, Wayland MT, Webster MJ, Bahn S. Gene
expression analysis of bipolar disorder reveals downregulation of the ubiquitin cycle and
alterations in synaptic genes. Mol Psychiatry 2006; 11: 965–978.
18. Higgs BW, Elashoff M,RichmanS, Barci B. An online database for brain disease research.
BMC Genomics 2006; 7: 70.
19. Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate
variable analysis. PLoS Genet 2007; 3: 1724–1735.
20. Liu C, Cheng L, Badner JA, Zhang D, Craig DW, Redman M et al. Whole-genome
association mapping of gene expression in the human prefrontal cortex. Mol Psychiatry
2010; 15: 779–784.
21. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D et al. PLINK: a tool
set for whole-genome association and population-based linkage analyses. Am J Hum
Genet 2007; 81: 559–575.
22. Pei YF, Li J, Zhang L, Papasian CJ, Deng HW. Analyses and comparison of accuracy of
different genotype imputation methods. PLoS One 2008; 3: e3551.
23. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network
analysis. BMC Bioinformatics 2008; 9: 559.
24. Gargalovic PS, Imura M, Zhang B, Gharavi NM, Clark MJ, Pagnon J et al. Identiﬁcation of
inﬂammatory gene modules based on variations of human endothelial cell responses to
oxidized lipids. Proc Natl Acad Sci USA 2006; 103: 12741–12746.
25. Hu Z, Mellor J, Wu J, DeLisi C. VisANT: an online visualization and analysis tool for
biological interaction data. BMC Bioinformatics 2004; 5: 17.
26. Dennis Jr G, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC et al. DAVID: Database
for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003; 4:P 3 .
27. Mirnics K, Levitt P, Lewis DA. DNA microarray analysis of postmortem brain tissue. Int Rev
Neurobiol 2004; 60: 153–181.
28. Fare TL, Coffey EM, Dai H, He YD, Kessler DA, Kilian KA et al. Effects of atmospheric
ozone on microarray data quality. Anal Chem 2003; 75: 4672–4675.
29. Leek JT, Scharpf RB, Bravo HC, Simcha D, Langmead B, Johnson WE et al. Tackling the
widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet
2010; 11: 733–739.
30. McCallMN,BolstadBM,IrizarryRA.Frozenrobustmultiarrayanalysis(fRMA).Biostatistics
2010; 11: 242–253.
31. Torkamani A, Dean B, Schork NJ, Thomas EA. Coexpression network analysis of neural
tissue reveals perturbations in developmental processes in schizophrenia. Genome Res
2010; 20: 403–412.
32. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in
the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley
Neuropathology Consortium. Schizophr Res 2004; 67: 269–275.
33. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of
schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex.
Neuron 2000; 28: 53–67.
34. Kim S, Webster MJ. Correlation analysis between genome-wide expression proﬁles
and cytoarchitectural abnormalities in the prefrontal cortex of psychiatric disorders.
Mol Psychiatry 2010; 15: 326–336.
35. McInnes LA, Lauriat TL. RNA metabolism and dysmyelination in schizophrenia. Neurosci
Biobehav Rev 2006; 30: 551–561.
36. Huang HS, Matevossian A, Whittle C, Kim SY, Schumacher A, Baker SP et al. Prefrontal
dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone
methylation at GABAergic gene promoters. J Neurosci 2007; 27: 11254–11262.
37. Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR et al. DISC1 and
PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling.
Science 2005; 310: 1187–1191.
38. Wong ML, Whelan F, Deloukas P, Whittaker P, Delgado M, Cantor RM et al. Phospho-
diesterase genes are associated with susceptibility to major depression and anti-
depressant treatment response. Proc Natl Acad Sci USA 2006; 103: 15124–15129.
39. Fatemi SH, King DP, Reutiman TJ, Folsom TD, Laurence JA, Lee S et al. PDE4B
polymorphisms and decreased PDE4B expression are associated with schizophrenia.
Schizophr Res 2008; 101: 36–49.
40. FatemiSH,ReutimanTJ,FolsomTD,LeeS.Phosphodiesterase-4Aexpressionisreduced
in cerebella of patients with bipolar disorder. Psychiatr Genet 2008; 18: 282–288.
41. Fatemi SH, Folsom TD, Reutiman TJ, Vazquez G. Phosphodiesterase signaling system is
disrupted in the cerebella of subjects with schizophrenia, bipolar disorder, and major
depression. Schizophr Res 2009; 119: 266–267.
42. Numata S, Iga J, Nakataki M, Tayoshi S, Taniguchi K, Sumitani S et al. Gene expression
and association analyses of the phosphodiesterase 4B (PDE4B) gene in major depressive
disorder in the Japanese population. Am J Med Genet B Neuropsychiatr Genet 2009;
150B: 527–534.
43. Hennah W, Porteous D. The DISC1 pathway modulates expression of neuro-
developmental, synaptogenic and sensory perception genes. PLoS One 2009; 4: e4906.
44. Wolosker H, Blackshaw S, Snyder SH. Serine racemase: a glial enzyme synthesizing D-
serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc Natl Acad Sci
USA 1999; 96: 13409–13414.
45. Leeson PD, Iversen LL. The glycine site on the NMDA receptor: structure-activity
relationships and therapeutic potential. J Med Chem 1994; 37: 4053–4067.
46. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of
schizophrenia. J Psychiatr Res 1999; 33: 523–533.
47. BelforteJE,ZsirosV,SklarER,JiangZ,YuG, LiYetal.PostnatalNMDA receptorablation
in corticolimbic interneurons confers schizophrenia-like phenotypes. Nat Neurosci 2010;
13: 76–83.
48. VerrallL,BurnetPW,BettsJF,Harrison PJ.TheneurobiologyofD-aminoacid oxidaseand
its involvement in schizophrenia. Mol Psychiatry 2010; 15: 122–137.
49. Bendikov I, Nadri C, Amar S, Panizzutti R, De Miranda J, Wolosker H et al. A CSF and
postmortem brain study ofD-serinemetabolic parameters in schizophrenia. Schizophr Res
2007; 90: 41–51.
50. VerrallL,Walker M,RawlingsN,Benzel I,Kew JN, Harrison PJetal. d-Aminoacid oxidase
and serine racemase in human brain: normal distribution and altered expression in
schizophrenia. Eur J Neurosci 2007; 26: 1657–1669.
51. Steffek AE, Haroutunian V, Meador-Woodruff JH. Serine racemase protein expression in
cortex and hippocampus in schizophrenia. NeuroReport 2006; 17: 1181–1185.
52. Grabowski PJ, Black DL. Alternative RNA splicing in the nervous system. Prog Neurobiol
2001; 65: 289–308.
53. Sartorius LJ, Weinberger DR, Hyde TM, Harrison PJ, Kleinman JE, Lipska BK. Expression
of a GRM3 splice variant is increased in the dorsolateral prefrontal cortex of individuals
carrying a schizophrenia risk SNP. Neuropsychopharmacology 2008; 33: 2626–2634.
54. Law AJ, Kleinman JE, Weinberger DR, Weickert CS. Disease-associated intronic variants
in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in
schizophrenia. Hum Mol Genet 2007; 16: 129–141.
55. Knable MB, Barci BM, Bartko JJ, Webster MJ, Torrey EF. Molecular abnormalities in the
major psychiatric illnesses: Classiﬁcation and Regression Tree (CRT) analysis of post-
mortem prefrontal markers. Mol Psychiatry 2002; 7: 392–404.
56. Knable MB, Torrey EF, Webster MJ, Bartko JJ. Multivariate analysis of prefrontal cortical
data from the Stanley Foundation Neuropathology Consortium. Brain Res Bull 2001; 55:
651–659.
57. PrabakaranS,SwattonJE,RyanMM,HuffakerSJ,HuangJT,GrifﬁnJLetal.Mitochondrial
dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative
stress. Mol Psychiatry 2004; 9: 684–697, 643.
58. Cheung VG, Spielman RS, Ewens KG, Weber TM, Morley M, Burdick JT. Mapping
determinants ofhuman gene expression byregionalandgenome-wideassociation.Nature
2005; 437: 1365–1369.
59. Beasley CL, Zhang ZJ, Patten I, Reynolds GP. Selective deﬁcits in prefrontal cortical
GABAergic neurons in schizophrenia deﬁned by the presence of calcium-binding proteins.
Biol Psychiatry 2002; 52: 708–715.
60. Lewis DA, Hashimoto T, Morris HM. Cell and receptor type-speciﬁc alterations in markers
of GABA neurotransmission in the prefrontal cortex of subjects with schizophrenia.
Neurotox Res 2008; 14: 237–248.
61. Vostrikov VM, Uranova NA, Orlovskaya DD. Deﬁcit of perineuronal oligodendrocytes
in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res 2007; 94:
273–280.
62. Webster JA, Gibbs JR, Clarke J, Ray M, Zhang W, Holmans P et al. Genetic control of
human braintranscript expression in Alzheimer disease. AmJHumGenet2009; 84: 445–458.
Translational Psychiatry is an open-access journal
published by Nature Publishing Group. This work is
licensed under the Creative Commons Attribution-Noncommercial-No
DerivativeWorks3.0Unported License. To viewacopyofthis license,
visit http://creativecommons.org/licenses/by-nc-nd/3.0/
Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)
Cis eQTLs in various brain regions
S Kim et al
8
Translational Psychiatry